gamma-aminobutyric acid type A receptor subunit alpha 5
RGD ID:
61859
Description:
Enables GABA receptor binding activity; GABA-A receptor activity; and transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potential. Involved in chemical synaptic transmission. Located in dendrite and neuronal cell body membrane. Part of receptor complex. Is active in GABA-ergic synapse; postsynaptic specialization membrane; and presynaptic membrane. Human ortholog(s) of this gene implicated in bipolar disorder; depressive disorder; and developmental and epileptic encephalopathy 79. Orthologous to human GABRA5 (gamma-aminobutyric acid type A receptor subunit alpha5); INTERACTS WITH (+)-pilocarpine; (S)-nicotine; 2,3,7,8-tetrachlorodibenzodioxine.
bacoside A inhibits the reaction [Pilocarpine results in decreased expression of GABRA5 mRNA], Carbamazepine inhibits the reaction [Pilocarpine results in decreased expression of GABRA5 mRNA]
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GABRA5 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GABRA5 mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GABRA5 mRNA
[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GABRA5 mRNA
[NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GABRA5 mRNA